TAK-715 - p38 MAPK 抑制剂 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemETAK-715Cat. No.: HY-10456CAS No.: 303162-79-0分式: CHNOS分量: 399.51作靶点: p38 MAPK作通路: MAPK/ERK Pathway储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 100 mg/mL (250.31 mM)H2O : 40% PEG300 5% Tw

2、een-80 45% salineSolubility: 2.5 mg/mL (6.26 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (6.26 mM); Clear solution1/2 Master of Small Molecules 您边的抑制剂师www.MedChemEBIOLOGICAL ACTIVITY物活性 TAK-715p38 MAPK选择性抑制剂，IC50为7.1 nM，对p38/，JNK1，ERK1，IKK，MEKK1和TAK1抑制性。户使本产品发表的科研献 Sc

3、i Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. J Invest Dermatol. 2019 Jan;139(1):224-234. Front Pharmacol. 2018 Jun 21;9:660. Harvard Medical School LINCS LIBRARYSee more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Miwatashi S, et al. Novel inhibitor of p38 MAP kinase as an anti

4、-TNF-alpha drug: discovery of N-4-2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl-2-pyridylbenzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J Med Chem, 2005, 48(19), 5966-5979.2. Verkaar F, et al. Inhibition of Wnt/-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase I/?. Chem Biol, 2011, 18(4), 485-494.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792;F